The drug fits well into our product portfolio, which already contains medicine against adverse effects of chemotherapeutics.

nbsp;are now being tested in clinical trials to prevent tumor cells from resisting harsh chemotherapeutics.

Tardugno will provide an update on the company's activities, including execution of the company's strategy to achieve two critical goals: the clinical success and regulatory approval of our initial cancer fighting drug, Thermodox([R]), and, at the same time, the identification, development and growth of a solid pipeline of additional chemotherapeutics having the potential for treatment of additional indications.